NCT02244125 2025-11-24
PCD
Institut Curie
Phase 2 Completed
Clinical Trials
8 trialsNCT02043847 2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1 Completed
NCT01660633 2020-04-21
Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation
Acrotech Biopharma Inc.
Phase 2 Completed
NCT02043860 2019-10-14
BMT-02
University of Illinois at Chicago
Phase 1 Terminated
NCT00024466 2018-09-19
Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT02353572 2015-03-09
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
University of Colorado, Denver
Phase 1/2 Terminated
NCT00950768 2009-08-03
Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients
Azienda Ospedaliera San Giovanni Battista
Phase 3 Completed
NCT00560053 2008-11-27
Pethema Multiple Myeloma 2000
PETHEMA Foundation
Phase 3 Completed